Skip to Content

News

Printer-friendly Send by email PDF version
  • February 6, 2015

    The Honourable Rona Ambrose, Minister of Health, on behalf of her colleague, the Honourable Ed Holder, Minister of State (Science and Technology), today announced that GlycoNet, a new national research network, is receiving $27.3 million over five years to develop new drugs and vaccines for conditions such as influenza, genetic diseases and diabetes.

    GlycoNet will build on Canada's international leadership in glycomics during the last 50 years. GlycoNet researchers will analyze the function of glycomes (or carbohydrates) in the body and find ways to take advantage of their...

  • November 28, 2014

    Research investigates use of biomass resources to replace petrochemicals

    The University of British Columbia is part of a new research initiative aimed at upgrading the sustainability of Canada’s industrial sector by replacing its lifeblood — petrochemicals — with green alternatives.

    UBC, Concordia University and the University of Toronto make up the Industrial Biocatalysis Network (IBN). The creation of IBN was announced today by the Natural Sciences and Engineering Research Council of Canada (NSERC). It is a five-year, $5 million program, part of the federal government’s...

  • November 17, 2014

    A new Canadian research network to study rare diseases and how genetic mutations cause these diseases will be established with a $2.3 million grant from the Canadian Institutes for Health Research (CIHR).

    The Canadian Rare Diseases Models and Mechanisms (RDMM) Network is led by Philip Hieter, a Professor of Medical Genetics, along with Kym Boycott, senior scientist at the Children’s Hospital of Eastern Ontario (CHEO), and Janet Rossant, senior scientist at The Hospital for Sick Children (SickKids).

    The network...

  • October 22, 2014

    A new finding by UBC Centre for Blood Research scientist Wilf Jefferies and his collaborators, demonstrates that T-Lymphocytes, a type of immune cell that learns to recognize and attack microbial pathogens and cancer, are activated by the TRPV1 pain receptor. The study entitle “TRPV1 channel regulates CD4+ T cell activation and pro-inflammatory properties” was published in ...

  • September 29, 2014

    Congratulations to Dr. Brett Finlay who has been awarded the Prix Galien Canada Research Award 2014!

    The Prix Galien is the most prestigious award in the field of Canadian pharmaceutical research and innovation. Referred to as the Nobel Prize of pharmaceutical research, it recognizes the efforts and achievements of pharmaceutical research and development. The Prix Galien Canada is a branch of Innovation Life Canada. The Prix Galien Canada Research Award is presented to the researcher or the research team...

Syndicate content